Natus Medical Incorporated (NASDAQ:BABY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday. The firm presently has a $41.00 price target on the stock. Zacks Investment Research’s price target would suggest a potential upside of 8.18% from the company’s previous close.

According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “

A number of other research analysts have also recently commented on BABY. Off Wall Street began coverage on Natus Medical in a research note on Friday, December 16th. They set a “sell” rating on the stock. Raymond James Financial, Inc. upgraded Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price target on the stock in a research note on Tuesday, September 13th. Finally, Benchmark Co. began coverage on Natus Medical in a research note on Tuesday, October 4th. They set a “buy” rating and a $55.00 price target on the stock. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $45.25.

Shares of Natus Medical (NASDAQ:BABY) opened at 38.30 on Wednesday. Natus Medical has a 12 month low of $29.54 and a 12 month high of $44.39. The firm has a market cap of $1.24 billion, a PE ratio of 31.14 and a beta of 1.10. The firm’s 50-day moving average price is $37.71 and its 200-day moving average price is $39.28.

Natus Medical (NASDAQ:BABY) last released its quarterly earnings results on Wednesday, October 19th. The company reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.05. Natus Medical had a return on equity of 13.53% and a net margin of 10.89%. The company had revenue of $90.90 million for the quarter, compared to analysts’ expectations of $89.94 million. During the same period in the prior year, the firm earned $0.39 earnings per share. The firm’s revenue was down 3.9% compared to the same quarter last year. Analysts expect that Natus Medical will post $1.64 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades Natus Medical Incorporated (BABY) to Buy” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was stolen and reposted in violation of United States & international copyright law. The legal version of this report can be accessed at http://www.dailypolitical.com/2017/01/13/zacks-investment-research-upgrades-natus-medical-incorporated-baby-to-buy.html.

In related news, insider James B. Hawkins acquired 10,000 shares of Natus Medical stock in a transaction dated Thursday, October 27th. The shares were acquired at an average cost of $38.30 per share, for a total transaction of $383,000.00. Following the completion of the purchase, the insider now owns 469,725 shares in the company, valued at $17,990,467.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Robert A. Gunst sold 3,250 shares of the stock in a transaction on Monday, October 24th. The shares were sold at an average price of $41.92, for a total value of $136,240.00. Following the completion of the sale, the director now owns 51,150 shares in the company, valued at $2,144,208. The disclosure for this sale can be found here. 4.80% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in the stock. Acrospire Investment Management LLC boosted its stake in shares of Natus Medical by 39.1% in the second quarter. Acrospire Investment Management LLC now owns 2,844 shares of the company’s stock valued at $108,000 after buying an additional 800 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Natus Medical by 36.0% in the second quarter. BlackRock Inc. now owns 3,096 shares of the company’s stock valued at $117,000 after buying an additional 820 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Natus Medical by 72.6% in the third quarter. Tower Research Capital LLC TRC now owns 3,327 shares of the company’s stock valued at $131,000 after buying an additional 1,399 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Natus Medical during the third quarter valued at about $156,000. Finally, PineBridge Investments L.P. boosted its stake in shares of Natus Medical by 3.7% in the second quarter. PineBridge Investments L.P. now owns 4,200 shares of the company’s stock valued at $159,000 after buying an additional 149 shares during the last quarter. Institutional investors and hedge funds own 83.94% of the company’s stock.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

5 Day Chart for NASDAQ:BABY

Get a free copy of the Zacks research report on Natus Medical (BABY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.